TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05960487

Intervention type: OTHER
Intervention: Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)
Description: Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.

Intervention type: OTHER
Intervention: Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)
Description: Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.
Study: NCT06509711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLYOMETRICS jump training with HIIT (4 weeks,3 sessions per week)
Description: First set of drills 6 x 40-cm hurdle jumps +5-s sprint\* at 130% of aerobic maximum speed. Second set of drills 6 x 30-cm hurdle jumps with extended legs + 5-s sprint at 130% of aerobic maximum speed. Third set of drills 6 x horizontal jumps + 5-s sprint at 130% of aerobic maximum speed. Fourth set of drills 3 right-leg and 3left-leg hops +5-s sprint at 130% of aerobic maximum speed. Each drills set was performed 2 times in a row. Afterwards, 10 seconds of rest were allowed. Thereafter, this sequence of effort-rest was repeated 8 times. After then, a 3-5 min recovery period was allowed before commencing the next drills set;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLYOMETRICS JUMP TRAINING WITHOUT HIIT (4weeks, 3sessions Per week)
Description: Plate pogo (4 reps, 3 sets) Broad jump( 4reps,3 sets)
Study: NCT05397483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Legal Education plus Trauma-informed Therapy (LETiT)
Description: Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention As Usual (IAU)
Description: Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
Study: NCT06259136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A transitional palliative care intervention
Description: The Pal-Cycles intervention starts just before the care transition from curative oncology care to palliative care with a goals of care conversation between a hospital care provider and the patient. The conversation will be recorded in a summary of treatment and care form which will be completed by a hospital based clinician based on the key elements of the conversation with the patient and the treatment and care plan. Afterwards a (digital) copy of the form is given to the patient and another copy is sent to the general practitioner in combination with the discharge letter.
Study: NCT05563168

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DILTIAZEM TEVA 60 mg or placebo
Description: DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DILTIAZEM TEVA 60 mg or placebo
Description: DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.
Study: NCT05570032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
Study: NCT05454280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensified post-discharge surveillance
Description: * TCC Nurse Televisit at post-discharge day 1 and 7~* Televisit with APP/Resident/Fellow between post-discharge day 3-5~* Referral for home health nursing evaluation upon discharge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-discharge surveillance
Description: Patients in the Control Arm will receive standard post-discharge surveillance, as deemed appropriate/necessary by the surgeons caring for them at the time of hospital discharge.
Study: NCT06648486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With the assistance of wearable isokinetic training robot
Description: A child with SMA will use a wearable isokinetic training robot to train the knee joint for 20 sessions.
Study: NCT06356168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Virtual Reality
Description: Participants interact using virtual reality during dialysis.
Study: NCT05741086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: evolocumab (140 mg every 2 weeks)
Study: NCT06356168

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Virtual Reality
Description: Participants use virtual reality alone during dialysis.
Study: NCT04870151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterolateral approach
Description: Cemented hemiarthroplasty using an anterolateral approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct lateral approach
Description: Cemented hemiarthroplasty using a direct lateral approach.
Study: NCT05788601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapiglutide
Description: GLP-1/GLP-2 receptor agonism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapiglutide
Description: GLP-1/GLP-2 receptor agonism

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05004662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered automated treatment
Description: An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will be provided with a 10-week supply of nicotine patches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will be provided with a 10-week supply of nicotine patches

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counceling
Description: Phone counseling with the Florida Quitline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Participants will be provided with a 10-week supply of nicotine lozenges

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenge
Description: Participants will be provided with a 10-week supply of nicotine lozenges
Study: NCT04736472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic test
Description: Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
Study: NCT05914194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLS-2
Description: Participants will receive NLS-2 tablets orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive NLS-2 matching placebo tablets orally.
Study: NCT06544408

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool B70 AP Coil - Active (dl-PFC)
Description: One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cool B70 AP Coil- Sham (dl-PFC)
Description: One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool D-B80 AP Coil - Active (dm-PFC)
Description: One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cool D-B80 AP Coil - Sham (dm-PFC)
Description: One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cool B70 Treatment Coil - Active Only
Description: The treatment will be the same as the left dl-PFC accel-TMS dl-PFC except that the Cool B70 Treatment coil only has an active treatment coil.
Study: NCT06504940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib combined with bendamustine and rituximab
Description: they will receive three cycles of Orelabrutinib combined with bendamustine and rituximab (BR: bendamustine 70mg/m\^2 on days 1-2; rituximab 375mg/m\^2 on day 0). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 21 cycles, each cycle 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib combined with obinutuzumab
Description: they will receive six cycles of Orelabrutinib combined with obinutuzumab (G 1000mg iv on days 1, 8, 15 of cycle 1, and day 1 of cycles 2-6; Orelabrutinib 150mg once daily). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 18 cycles, each cycle 28 days ).
Study: NCT05741086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20-40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20-40mg
Study: NCT05552118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cochlear™ Remote care
Description: Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)
Description: CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implant CI600 Series, CI500 Series or Freedom Series and Sound processor Nucleus 7 or Kanso 2 (or latest compatible Sound Processor)
Description: CI600 Series (CI612, CI622, CI632), CI500 Series (CI512, CI522, CI532), Freedom Series (CI24RE(CA), CI24RE(ST), CI422). Nucleus 7 (CP1000) or Kanso 2 (CP1050)
Study: NCT06381336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRAK-SILVER platform
Description: The Experimental Group used TRAK-SILVER, a cross-platform web application that empowers healthcare professionals and patients. It facilitates the management of a patient's condition by providing therapeutic exercises, monitoring activity, and administering clinical assessment scales and questionnaires. The platform's advanced artificial vision algorithm, known for its precision, enhances patient engagement with real-time measurements and corrections during exercise.~Physiotherapists monitored the sessions through the TRAK-SILVER platform's monitoring system and weekly phone calls. The TRAK-SILVER platform had an alert notification system.~The program's second part involved weekly uploads of health-promoting information pills to the platform.
Study: NCT05753215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline Pill
Description: Omadacycline will be administered 300 mg orally daily without the loading dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
Study: NCT05203666

Intervention type: OTHER
Intervention: percutaneous removable interspinous process
Description: percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
Study: NCT05568693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.3ml of mRNA vaccine
Description: Subjects received 0.3ml of mRNA vaccine intramuscularly
Study: NCT06091228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tongue scraper
Description: tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tongue scraper
Description: tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue
Study: NCT06414070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jenga Dada
Description: Jenga Dada aims to empower women participating in community-based economic groups by training them to recognize inequality, challenge it, and work toward positive changes in their lives related to finances, health, and relationships and increase social support on these issues within the groups. Jenga Dada is expected to include eight modules: 1) overview of the intervention, 2) gender roles, 3) economic control and abuse, 4) intimate partner violence (IPV), 5) reproductive coercion (RC), 6) family planning (FP), 7) financial literacy, and 8) life goals. The Jenga Dada intervention is group discussion-based and draws on two effective interventions: ARCHES (a facility-based contraceptive counseling intervention providing support for RC and IPV) and Girls Invest (a mobile health application with integrated modules on gender, IPV, and financial literacy). The intervention will be facilitated by a local NGO in partnership with group leaders.
Study: NCT06263062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness-Based Coping with Fear of Cancer Programme
Description: The content of the Training Program was created by researchers based on MBSR, in line with high-level research results and international guides.Then, the necessary arrangements were made bytaking the opinions of 10 experts ( faculty members of the department of obstetrics and gynaecology nursing, psychiatry specialist, faculty members of the gynaecology oncology department, oncology clinic psychologist, obstetrics and gynaecology clinic charge nurse). Content concluded in accordance with the comments received.
Study: NCT04817566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
Study: NCT05827380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait adaptability training
Description: During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
Study: NCT05410691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handheld US device
Description: Handheld US-guided AVF/AVG cannulation
Study: NCT05175053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Description: Continuous renal replacement therapy using continuous venovenous hemodiafiltration (CVVHDF)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: The best medical management continues until the patient meets absolute indication of renal replacement therapy
Study: NCT05627167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: day time cyclic nutrition
Description: Continuous isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100 mL for 10 hours during the day (e.g. 08:00 to 18:00), via nasal or oro-gastric tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous nutrition
Description: Isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100ml, continuously 24 hours a day by nasal or oro-gastric tube
Study: NCT04865146

Intervention type: DEVICE
Intervention: TRIGEN™ INTERTAN™
Description: Femoral fracture treated with INTERTAN 10S Nail
Study: NCT05900765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab 240mg
Description: AVD regimen:~Doxorubicin 25mg/m2, d1, d15, IV; Vincristine 3mg/m2, d1, d15 IV; Dacarbazine 0.375mg/m2, d1, d15 IV
Study: NCT06516250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual serious game GEMAS
Description: Implement and evaluate a virtual serious game designed to improve the learning and retention of clinical knowledge in medicine and nursing students and residents through the simulation of clinical cases in a hospital emergency environment.
Study: NCT04876989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-SGB
Description: Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-TPVB
Description: Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
Study: NCT05693090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration
Study: NCT06382363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POC-cHbA1c testing
Description: The point-of-care HbA1c instrument employed in this study will be the Cobas b 101 (Roche Diagnostics, Switzerland) diagnostic test system. A capillary blood sample will be obtained by dermal puncture of a fingertip using a disposable lancet and resorbed in the specially marked area of the Cobas b 101 test disc. The disc will be inserted in the autoanalyzer. Test results displayed in both % and mmol/l will be available within 10 minutes.
Study: NCT05896046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554+ SHR1701
Description: SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701
Description: Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
Study: NCT06418776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive therapy
Description: Intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity therapy
Description: Low intensity therapy (Aza+Ven, Dac+Ven, LDARA-C+Ven)
Study: NCT04476576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (experimental)
Description: 3 times per week, 30 minutes each time. Entrance in heat: 8-10 min of joint mobility and / or the aerobic exercise in the main part at light intensity (OMNI 3-4) Main part: minimum 30 minutes, maximun 60 minutes. Intensity: moderate, guided by Talk Test and effort perception scale 5-6 OMNI. Type: aerobic, cycling or walking at home using a treadmill or exercise bike and / or cycling and walking outdoors according to the patient's possibilities and preferences. Return to calm: 5 min of aerobic physical activity of main part at mild intensity (OMNI 3-4), then static stretching. Pictures with each type of exercise will be offered and detailed explained.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility exercise (active comparator)
Description: Entrance in heat: 10 min of joint mobility. Main part: Minimum 30 minutes. Frequency: 3 times por week Intensity: The patient should be able to slowly stretch the muscle to a position of mild discomfort. Type: Static Stretch Time: 15-30 seconds 2 repetitions of each stretch Number of exercises: 12 . Pictures with each muscle group to exercise will be offered and detailed explained.